106 results
8-K
EX-99.1
SYRS
Syros Pharmaceuticals Inc.
15 Sep 22
Departure of Directors or Certain Officers
4:06pm
of an Award or (ii) satisfy tax withholding obligations with respect to Awards (including shares retained from the Award creating the tax obligation) shall … sufficient funds to pay the exercise price and any required tax withholding or (ii) delivery by the Participant to the Company of a copy of irrevocable
424B5
SYRS
Syros Pharmaceuticals Inc.
19 Dec 23
Prospectus supplement for primary offering
4:53pm
of the pre-funded warrants
S-15
Material U.S. federal income and estate tax considerations for non-U.S. holders of common stock
S-17
Underwriting
S … -16
Material U.S. federal income and estate tax considerations for non-U.S. holders of our common stock and pre-funded warrants
The following
424B5
SYRS
Syros Pharmaceuticals Inc.
4 Apr 19
Prospectus supplement for primary offering
4:15pm
Capitalization
S-15
Dilution
S-16
Dividend Policy
S-18
Description of securities we are offering
S-19
Material U.S. federal tax considerations for holders … Trust Company, N.A.
Warrant Agent
Our warrant agent is Computershare Trust Company, N.A.
S-22
MATERIAL U.S. FEDERAL TAX CONSIDERATIONS
424B5
SYRS
Syros Pharmaceuticals Inc.
4 Apr 19
Prospectus supplement for primary offering
4:13pm
Policy
S-17
Description of securities we are offering
S-18
Material U.S. federal tax considerations for holders of our common stock and warrants
S-20 … ) is Computershare Trust Company, N.A.
Warrant Agent
Our warrant agent is Computershare Trust Company, N.A.
S-19
MATERIAL U.S. FEDERAL TAX
424B5
SYRS
Syros Pharmaceuticals Inc.
8 Apr 19
Prospectus supplement for primary offering
12:00am
of proceeds
S-14
Capitalization
S-15
Dilution
S-16
Dividend Policy
S-18
Description of securities we are offering
S-19
Material U.S. federal tax considerations … . FEDERAL TAX CONSIDERATIONS FOR HOLDERS OF
SERIES A PREFERRED STOCK AND WARRANTS
The following discussion describes the material U.S. federal income tax
424B5
mnl4lkofm1osi7
8 Apr 19
Prospectus supplement for primary offering
12:00am
424B5
kg9pasq2et5733
20 Jan 21
Prospectus supplement for primary offering
4:02pm
424B5
4r3ub71usz8num50d26l
19 Jan 21
Prospectus supplement for primary offering
4:06pm
S-4
EX-10.5
nmo7kn 1a6m4jm5
18 Jul 22
Registration of securities issued in business combination transactions
7:58am
8-K
EX-2.1
bdnqbygfw2h6s2m54
7 Dec 20
Entry into a Material Definitive Agreement
6:05am
424B3
07zp9 0z52c8r7d3p22f
8 Aug 22
Prospectus supplement
5:47pm
8-K
EX-2.1
nl3xnaasjfdsk7roxlg
5 Jul 22
Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement
7:07am
8-K
EX-10.2
5jzku
13 Oct 21
Departure of Directors or Certain Officers
4:01pm
425
1xuvf27zzcowdfj
15 Sep 22
Business combination disclosure
4:08pm